
H.I.G. Capital Finalizes Sale of BIOVECTRA
H.I.G. Capital (“H.I.G.”), a prominent global alternative investment firm with $65 billion in capital under management, has successfully sold its portfolio company, BIOVECTRA Inc. (“BIOVECTRA” or the “Company”), a leading contract development and manufacturing organization (CDMO) specializing in active pharmaceutical…
















